RMOC briefing on adalimumab – March 2018

This briefing paper is provided through the RMOC system to summarise:

  • Advice to commissioners and providers related to next steps with best-value adalimumab uptake
  • Planning associated with the patent expiry of the originator product: Humira
AdalimumabBiosimilar medicineNewsRMOC medicines optimisation recommendations and resourcesRMOC new medicines recommendation

Attachments